Article
Materials Science, Multidisciplinary
Piers Turner, Keith R. Paton, Elizabeth J. Legge, Andres de Luna Bugallo, A. K. S. Rocha-Robledo, Ahmed-Azmi Zahab, Alba Centeno, Alessio Sacco, Amaia Pesquera, Amaia Zurutuza, Andrea Mario Rossi, Diana N. H. Tran, Diego Silva, Dusan Losic, Farzaneh Farivar, Hugo Kerdoncuff, Hyuksang Kwon, Jerome Pirart, Joao Luiz E. Campos, Kiran M. Subhedar, Li-Lin Tay, Lingling Ren, Luiz Gustavo Cancado, Matthieu Paillet, Paul Finnie, Pei Lay Yap, Raul Arenal, Sanjay R. Dhakate, Sebastian Wood, Sergio Jimenez-Sandoval, Tim Batten, Vaiva Nagyte, Yaxuan Yao, Angela R. Hight Walker, Erlon H. Martins Ferreira, Cinzia Casiraghi, Andrew J. Pollard
Summary: This study presents an international interlaboratory comparison (ILC) on Raman spectroscopy measurements of chemical vapor deposition (CVD) grown graphene, focusing on the comparability of measurements and addressing measurement uncertainty contributions and solutions for improved accuracy and precision.
Article
Medical Laboratory Technology
Veerle Bossuyt, Rosanna Lau, Brandon Young, John Greg Howe, Fengmin Zhao, Brian Leyland-Jones, Lili Du, Tiffany Foli, Christos Hatzis, W. Fraser Symmans
Summary: The study found that measurements of sensitivity to endocrine therapy assay (SET2,3) and its components were highly reproducible in intra- and interpathology laboratory settings.
CLINICAL CHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Javier Narbona, Luisa Hernandez-Baraza, Ruben G. Gordo, Laura Sanz, Javier Lacadena
Summary: Immunotoxins are chimeric molecules that combine the specificity of an antibody-based targeting domain and the cytotoxic potency of a toxin. This study designed and characterized several immunotoxin constructs using nanobodies as targeting domains against EGFR. The results confirm the therapeutic potential of a-sarcin-based nanoITXs.
Article
Materials Science, Multidisciplinary
M. Edwards, S. Rousseau, R. Novotny, B. Gong, M. Fulger, S. Penttila, A. Toivonen, A. Saez-Maderuelo, L. Zhang, D. Guzonas, X. Huang
Summary: This study reduced systemic differences between laboratories by unilateral preparation of coupons and unilateral chemical cleaning. The results showed significant mass loss of candidate materials for supercritical water-cooled reactors under experimental conditions, possibly due to factors such as mass transfer, galvanic and local corrosion.
JOURNAL OF NUCLEAR MATERIALS
(2022)
Article
Energy & Fuels
Joseph Karas, Ingrid Repins, Karl A. Berger, Bernhard Kubicek, Fangdan Jiang, Daqi Zhang, Jean-Nicolas Jaubert, Ana Belen Cueli, Tony Sample, Bengt Jaeckel, Matthias Pander, Esther Fokuhl, Max B. Koentopp, Friederike Kersten, Jun-Hong Choi, Birinchi Bora, Chandan Banerjee, Stefan Wendlandt, Tristan Erion-Lorico, Kenneth J. Sauer, Jon Tsan, Mauro Pravettoni, Mauro Caccivio, Giovanni Bellenda, Christos Monokroussos, Hamza Maaroufi
Summary: This paper reports the results of an international study on LETID on crystalline silicon PV modules. The reproducibility of LETID testing is within +/- 1% of maximum power. In LETID-sensitive modules, mean degradation is approximately 6% P-MP. LETID affects each cell in a module differently. Overall, this work has contributed to the development of a forthcoming standard for LETID testing.
PROGRESS IN PHOTOVOLTAICS
(2022)
Article
Oncology
Giovanni Randon, Rona Yaeger, Jaclyn F. Hechtman, Paolo Manca, Giovanni Fuca, Henry Walch, Jeeyun Lee, Elena Elez, Jenny Seligmann, Benedetta Mussolin, Filippo Pagani, Marco Maria Germani, Margherita Ambrosini, Daniele Rossini, Margherita Ratti, Francesc Salva, Susan D. Richman, Henry Wood, Gouri Nanjangud, Annunziata Gloghini, Massimo Milione, Alberto Bardelli, Filippo de Braud, Federica Morano, Chiara Cremolini, Filippo Pietrantonio
Summary: EGFR amplification is significantly associated with left primary tumor sidedness and RAS/BRAF wild-type status. EGFR-amplified tumors are usually MSS and HER2 nonamplified, with a higher median fraction of genome altered. Patients with EGFR amplification tend to have longer overall survival and better outcomes when exposed to anti-EGFR-based therapy.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Oncology
Lu Yang, Arup Bhattacharya, Yun Li, Sandra Sexton, Xiang Ling, Fengzhi Li, Yuesheng Zhang
Summary: Resistance to EGFR inhibitors in colorectal cancer is primarily due to the inability of the inhibitors to downregulate their target. The combination treatment with PEPDG278D overcomes this resistance.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Review
Immunology
Balakarthikeyan Janani, Mayakrishnan Vijayakumar, Kannappan Priya, Jin Hee Kim, D. S. Prabakaran, Mohammad Shahid, Sameer Al-Ghamdi, Mohammed Alsaidan, Nasraddin Othman Bahakim, Mohammad Hassan Abdelzaher, Thiyagarajan Ramesh
Summary: Colorectal carcinoma is a common and lethal form of cancer, with a high rate of metastasis. Targeted nanotherapy, particularly targeting EGFR, has the potential to improve surgical control and reduce tumor-related mortality. Antibodies conjugated with drug-loaded carriers can increase drug effectiveness and quantity delivered to the target site.
Article
Nanoscience & Nanotechnology
Tianjia Bu, Huifang Gao, Yaxuan Yao, Jianfeng Wang, Andrew J. Pollard, Elizabeth J. Legge, Charles A. Clifford, Alexandra Delvallee, Sebastien Ducourtieux, Malcolm A. Lawn, Bakir Babic, Victoria A. Coleman, Asa Jamting, Shan Zou, Maohui Chen, Zygmunt J. Jakubek, Erica Iacob, Narin Chanthawong, KittiSun Mongkolsuttirat, Guanghong Zeng, Clara Muniz Almeida, Bo-Ching He, Lachlan Hyde, Lingling Ren
Summary: Flake thickness is a crucial property of graphene-related 2D materials (GR2Ms), and reliable and accurate measurements with well-understood uncertainties are required. An international interlaboratory comparison project on thickness measurements of graphene oxide flakes has been completed, aiming to improve the equivalence of measurement methods. The methods, uncertainties, and analysis of the results are reported in this manuscript, which will directly contribute to the development of an ISO standard.
Review
Oncology
Pashtoon Murtaza Kasi, Manuel Geroy Afable, Cameron Herting, Mariusz Lukanowski, Zhaohui Jin
Summary: This review examines the molecular characteristics and clinical trials of anti-EGFR antibodies in the treatment of advanced colorectal cancer. It discusses the clinical implications of biomarkers for treatment selection, different dosing strategies, and side effect management. The review also explores future directions, particularly the combination of these antibodies with MAPK-targeted therapies and immunotherapy.
Article
Medicine, General & Internal
Tomotaka Ugai, Koichiro Haruki, Juha P. Vayrynen, Jennifer Borowsky, Kenji Fujiyoshi, Mai Chan Lau, Naohiko Akimoto, Rong Zhong, Junko Kishikawa, Kota Arima, Shan-Shan Shi, Melissa Zhao, Charles S. Fuchs, Xuehong Zhang, Marios Giannakis, Mingyang Song, Hongmei Nan, Jeffrey A. Meyerhardt, Molin Wang, Jonathan A. Nowak, Shuji Ogino
Summary: This study examined the association between coffee intake in colorectal cancer patients and survival. It was found that the correlation between coffee intake and colorectal cancer-specific mortality differed according to Crohn disease-like lymphoid reaction.
MAYO CLINIC PROCEEDINGS
(2022)
Review
Oncology
Davide Ciardiello, Giulia Martini, Vincenzo Famiglietti, Stefania Napolitano, Vincenzo De Falco, Teresa Troiani, Tiziana Pia Latiano, Javier Ros, Elena Elez Fernandez, Pietro Paolo Vitiello, Evaristo Maiello, Fortunato Ciardiello, Erika Martinelli
Summary: For patients with metastatic colorectal cancer (mCRC) who have progressed through first and second line treatments, the prognosis is poor and new therapeutic strategies are necessary. Emerging evidence suggests that retreatment with anti-EGFR monoclonal antibodies in the third line of therapy could lead to prolonged survival for patients who have previously benefitted from first-line therapy with anti-EGFR antibodies. The rationale behind this strategy is that after a break from anti-EGFR drugs, resistance in cancer cells may decline, making them sensitive to treatment with cetuximab and panitumumab.
Article
Oncology
Marcus Unterrainer, Christophe M. Deroose, Ken Herrmann, Markus Moehler, Lennart Blomqvist, Roberto Cannella, Caroline Caramella, Damiano Caruso, Manil D. Chouhan, Timm Denecke, Carolina De la Pinta, Lioe-Fee De Geus-Oei, Audrius Dulskas, Michel Eisenblatter, Kieran G. Foley, Sofia Gourtsoyianni, Frederic E. Lecouvet, Egesta Lopci, Monique Maas, Markus M. Obmann, Daniela E. Oprea-Lager, Joost J. C. Verhoeff, Ines Santiago, Sylvain Terraz, Melvin D'Anastasi, Daniele Regge, Andrea Laghi, Regina G. H. Beets-Tan, Volker Heinemann, Florian Lordick, Elizabeth C. Smyth, Jens Ricke, Wolfgang G. Kunz
Summary: This study aimed to establish an imaging protocol for colorectal cancer that promotes standardization and reduces variations. Through the formation of a multidisciplinary panel and the use of the Delphi method, the EORTC-ESOI-ESGAR core imaging protocol was identified.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Bernhard Doleschal, Andreas Petzer, Holger Rumpold
Summary: Anti-EGFR targeting is a key strategy in the treatment of metastatic colorectal cancer. Factors such as sidedness and RAS mutational status play a crucial role in predicting the efficacy of EGFR inhibitors. The use of liquid biopsy and next-generation sequencing allows for more personalized approaches in EGFR inhibition. This review critically examines the concepts of tackling the EGFR pathway in mCRC and explores the growing field of liquid biopsy guided personalized approaches in EGFR inhibition.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Marzia Di Donato, Erika Di Zazzo, Annamaria Salvati, Carmela Sorrentino, Giorgio Giurato, Donatella Fiore, Maria Chiara Proto, Monica Rienzo, Amelia Casamassimi, Patrizia Gazzerro, Maurizio Bifulco, Gabriella Castoria, Alessandro Weisz, Giovanni Nassa, Ciro Abbondanza
Summary: This study provides insights into the potential tumor-promoting functions of RIZ2 in CRC, demonstrating its involvement in EGF pathway deregulation and its impact on CRC cell behavior.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Hematology
Giulia Maggioni, Matteo Bersanelli, Erica Travaglino, Ana Alfonso Pierola, Annika Kasprzak, Arnan Sangerman Montserrat, Elisabetta Sauta, Claudia Sala, Tommaso Matteuzzi, Manja Meggendorfer, Matteo Gnocchi, Lin--Pierre Zhao, Cristina Astrid Tentori, Kathrin Nachtkamp, Daniele Dall'Olio, Ettore Mosca, Marta Ubezio, Alessia Campagna, Antonio Russo, Giulia Rivoli, Massimo Bernardi, Lorenza Borin, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Elena Saba, Saverio D'Amico, Luca Lanino, Benedetta Tinterri, Francesca Re, Marilena Bicchieri, Laura Giordano, Giovanni Angelotti, Pierandrea Morandini, Anne Sophie Kubasch, Francesco Passamonti, Alessandro Rambaldi, Victor Savevski, Armando Santoro, Arjan A. van de Loosdrecht, Alice Brogi, Valeria Santini, Shahram Kordasti, Guillermo Sanz, Francesc Sole, Norbert Gattermann, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Ulrich Germing, Maria Diez--Campelo, Matteo G. Della Porta
Summary: This study aimed to describe sex diversity in myelodysplastic syndromes and incorporate sex information into clinical decision-making. The study found differences between men and women in terms of disease genotype, phenotype, and clinical outcomes. Moreover, new prognostic models that included sex information were developed and performed better than the revised International Prognostic Scoring System.
LANCET HAEMATOLOGY
(2023)
Review
Oncology
Flavia Jacobs, Mariangela Gaudio, Chiara Benvenuti, Rita De Sanctis, Armando Santoro, Alberto Zambelli
Summary: Great progress has been made in personalized treatment for breast cancer oncology, with the introduction of genomic signature testing being particularly important. The aim of this review is to discuss the challenges and urgent issues related to its daily use, providing insights for better integration and wider application in clinical practice. The review focuses on the integration of genomic data with clinicopathological factors, the potential clinical impact of genomic testing in different patient populations and settings, and the optimization of test ordering.
Article
Hematology
Jasper J. P. Van Beek, Simone Puccio, Clara Di Vito, Federica De Paoli, Elisa Zaghi, Michela Calvi, Alice Scarpa, Clelia Peano, Gianluca Basso, Javier Cibella, Chiara De Philippis, Barbara Sarina, Inna Timofeeva, Rossana Capizzuto, Daniele Mannina, Rossana Mineri, Jacopo Mariotti, Roberto Crocchiolo, Armando Santoro, Luca Castagna, Stefania Bramanti, Domenico Mavilio, Enrico Lugli
Summary: In this study, longitudinal analysis of the lymphocyte compartment in 19 patients who underwent haplo-HSCT previously was performed. The study found that post-transplant infusion of CD45RA-depleted donor lymphocytes can selectively expand memory T-cell clones and provide protection against viral infections.
Review
Biochemistry & Molecular Biology
Federica Borea, Marika A. Franczak, Maria Garcia, Matteo Perrino, Nadia Cordua, Ryszard T. Smolenski, Godefridus J. Peters, Rafal Dziadziuszko, Armando Santoro, Paolo A. Zucali, Elisa Giovannetti
Summary: Malignant Pleural Mesothelioma (MPM) is a rare neoplasm that is usually diagnosed at an advanced stage and requires systemic treatment due to its ineligibility for radical surgery. Chemotherapy has been the standard treatment for 20 years until immune checkpoint inhibitors were introduced. However, the prognosis remains poor, and targeted therapies for MPM have mostly failed in clinical trials. This review aims to explore the potential reasons for treatment failures and determine the need for further research in this area.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Lin-Pierre Zhao, Juan Carlos Caballero Berrocal, Claudia Sala, Giulia Maggioni, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Borin, Saverio D'Amico, Cristina Astrid Tentori, Marta Ubezio, Alessia Campagna, Antonio Russo, Daniele Mannina, Luca Lanino, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Olivier Nibourel, Marilena Bicchieri, Niccolo' Bolli, Alessandro Rambaldi, Francesco Passamonti, Victor Savevski, Armando Santoro, Ulrich Germing, Shahram Kordasti, Valeria Santini, Maria Diez-Campelo, Guillermo Sanz, Francesc Sole, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta
Summary: The study validates the effectiveness of the Molecular International Prognostic Scoring System (IPSS-M) in predicting clinical outcomes of patients with myelodysplastic syndromes (MDS). IPSS-M improves the prognostic discrimination of the Revised International Prognostic Scoring System (IPSS-R) and enhances the accuracy of selecting candidates for hematopoietic stem cell transplantation (HSCT).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Filippo de Braud, Christophe Dooms, Rebecca S. Heist, Celeste Lebbe, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Rutkowski, Juergen Wolf, Paolo A. Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith McKean, Eva Munoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuan-Mai Couillebault, Helen Evans, Catarina D. Campbell, Sumit Basu, Michele Moschetta, Adil Daud
Summary: This study explores a targeted therapy for treating NRAS-mutant melanoma, showing promising antitumor activity in patients with the use of LXH254 and trametinib in combination.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Alessio Cortellini, Josep Tabernero, Uma Mukherjee, Ramon Salazar, Anna Sureda, Clara Maluquer, Daniela Ferrante, Mark Bower, Rachel Sharkey, Oriol Mirallas, Andrea Plaja, Marc Cucurull, Ricard Mesia, Alessia Dalla Pria, Thomas Newsom-Davis, Mieke Van Hemelrijck, Ailsa Sita-Lumsden, Eleanor Apthorp, Bruno Vincenzi, Giuseppina Rita Di Fazio, Giuseppe Tonini, Francesco Pantano, Alexia Bertuzzi, Sabrina Rossi, Joan Brunet, Matteo Lambertini, Paolo Pedrazzoli, Federica Biello, Francesca D'Avanzo, Alvin J. X. Lee, Marianne Shawe-Taylor, Lucy Rogers, Cian Murphy, Lee Cooper, Ramis Andaleeb, Saira Khalique, Samira Bawany, Sarah Ahmed, M. Carmen Carmona-Garcia, Roser Fort-Culillas, Raquel Linan, Federica Zoratto, Gianpiero Rizzo, Marta Perachino, Kris Doonga, Gianluca Gaidano, Riccardo Bruna, Andrea Patriarca, Clara Martinez-Vila, Ignacio Perez Criado, Raffaele Giusti, Francesca Mazzoni, Lorenzo Antonuzzo, Armando Santoro, Alessandro Parisi, Paola Queirolo, Avinash Aujayeb, Lorenza Rimassa, Nikolaos Diamantis, Rossella Bertulli, Claudia A. M. Fulgenzi, Antonio D'Alessio, Isabel Ruiz-Camps, Nadia Saoudi-Gonzalez, David Garcia Illescas, Irene Medina, Laura Fox, Alessandra Gennari, Juan Aguilar-Company, David J. Pinato
Summary: This study aimed to investigate the long-term effects of previous immunization on evolving variants of SARS-CoV-2. The study found that patients who received the vaccine had fewer sequelae after COVID-19, as well as a lower incidence of respiratory complications and prolonged fatigue. This finding is important for the treatment and survival of cancer patients.
Review
Oncology
Flavia Jacobs, Elisa Agostinetto, Chiara Miggiano, Rita De Sanctis, Alberto Zambelli, Armando Santoro
Summary: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options. Chemotherapy has been the mainstay, but recent studies have shown immune checkpoint inhibitors to be effective as first-line treatment for advanced TNBC expressing PD-L1. However, there are still many open questions regarding the use of immunotherapy in TNBC.
Review
Oncology
Chiara Benvenuti, Paola Tiberio, Mariangela Gaudio, Flavia Jacobs, Giuseppe Saltalamacchia, Sebastiano Pindilli, Alberto Zambelli, Armando Santoro, Rita De Sanctis
Summary: In breast cancer management, neoadjuvant chemotherapy is widely used, but there is a lack of technology that can predict the benefits of neoadjuvant chemotherapy for breast cancer patients. Circulating miRNAs have emerged as potential non-invasive biomarkers for breast cancer and may be useful in diagnosing, predicting, and prognosticating breast cancer patients undergoing neoadjuvant chemotherapy. Among circulating miRNAs, miR-21-5p and miR-34a-5p are the most promising biomarkers for breast cancer patients undergoing neoadjuvant chemotherapy.
Article
Oncology
Maria Susanna Grimaudo, Alice Laffi, Nicolo Gennaro, Roberta Fazio, Federico D'Orazio, Laura Sama, Licia Vanessa Siracusano, Federico Sicoli, Salvatore Lorenzo Renne, Armando Santoro, Alexia Francesca Bertuzzi
Summary: This case series describes the experience of using a personalized daily continuous administration of Regorafenib as an alternative regimen for treating metastatic GIST patients. The results show that this personalized schedule is safe and effective for these patients.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, Roberto Gabbiadini, Elisabetta Mastrorocco, Alessandro Quadarella, Alessandro Repici, Armando Santoro, Alessandro Armuzzi
Summary: The introduction of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has significantly changed the therapeutic algorithms for solid tumors. ICIs can lead to immune-related adverse events, with the gastrointestinal tract being commonly affected by varying levels of mucosal inflammation. The pathogenesis of checkpoint inhibitors colitis (CIC) is multifactorial and not fully understood, involving both anti-tumor activity and upregulation of specific inflammatory pathways. Treatment options for CIC, including biological therapy such as anti-TNF alpha, need to be further explored and prompt recognition and treatment are crucial.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cardiac & Cardiovascular Systems
Francesco Cannata, Giulio Stefanini, Carmelo Carlo-Stella, Mauro Chiarito, Stefano Figliozzi, Laura Novelli, Costanza Lisi, Sara Bombace, Cristina Panico, Francesca Cosco, Francesco Corrado, Giovanna Masci, Rita Mazza, Francesca Ricci, Lorenzo Monti, Giuseppe Ferrante, Armando Santoro, Marco Francone, Bruno R. da Costa, Peter Juni, Gianluigi Condorelli
Summary: The CONTROL trial aims to evaluate the cardioprotective effects of the beta blocker nebivolol in patients with breast cancer or diffuse large B cell lymphoma who will receive anthracyclines as part of their chemotherapy. This randomized, placebo-controlled, double-blinded trial will assess left ventricular ejection fraction reduction through cardiac magnetic resonance imaging at 12 months of follow-up.
JOURNAL OF CARDIOVASCULAR MEDICINE
(2023)
Article
Oncology
Lidija Antunovic, Alessia Artesani, Alessandro Vigano, Arturo Chiti, Armando Santoro, Martina Sollini, Silvia D. Morbelli, Rita De Sanctis
Summary: This study aimed to examine brain metabolic patterns on [F-18]Fluorodeoxyglucose ([F-18]FDG) positron emission tomography (PET) in breast cancer (BC), comparing patients with tension-type headache (TTH), migraine (MiG), and those without headache. The results showed that headache patients exhibited hypometabolism in specific brain regions before neoadjuvant chemotherapy (NAC) and headache patients with a good response to NAC showed hypermetabolic brain regions in the anterior medial frontal cortex.
Review
Oncology
Paola Tiberio, Mariangela Gaudio, Silvia Belloni, Sebastiano Pindilli, Chiara Benvenuti, Flavia Jacobs, Giuseppe Saltalamacchia, Alberto Zambelli, Armando Santoro, Rita De Sanctis
Summary: In recent decades, neoadjuvant chemotherapy has been proven to reduce tumor size and improve surgical outcomes in high-risk early or locally advanced breast cancer. However, individual responses to therapy and long-term prognosis remain unpredictable. Circulating microRNAs have emerged as potential non-invasive biomarkers for breast cancer management, but discrepancies between studies hinder their implementation in clinical practice.
Article
Oncology
Armando Santoro, Silvia Masini, Raffaele Cavina, Maria Chiara Tronconi, Fabio De Vincenzo
Summary: The use of immune checkpoint inhibitors can cause immune-related adverse events, including pancreatitis. Steroids are commonly used to treat pancreatitis induced by immune checkpoint inhibitors. However, little is known about the management of steroid-refractory cases. This case presentation suggests that rituximab may be an effective treatment option for such cases.
FRONTIERS IN ONCOLOGY
(2023)